SCHEMBL1229698

SCHEMBL1229698

O=C(NCCc1cccc(F)c1)c1sccc1Nc1ncnc2[nH]ccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 2/20 0.53
TTBK1 Q5TCY1 7/20 0.41
TTBK2 Q6IQ55 7/20 0.41
RET P07949 2/20 0.41
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
JAK3 P52333 1/20 0.39
SNCA P37840 1/20 0.39
EGFR P00533 2/20 0.39
AURKB Q96GD4 2/20 0.39
TNNI3K Q59H18 1/20 0.38
INCENP Q9NQS7 1/20 0.38
ABCB1 P08183 1/20 0.38
MKNK1 Q9BUB5 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
CDK2 P24941 1/20 0.38
FLT3 P36888 1/20 0.38
CCNA1 P78396 1/20 0.38
RPS6KB1 P23443 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1231369 0.90 BTK (0.53) BTKTTBK1TTBK2RETABCB1
SCHEMBL1231761 0.89 TTBK1 (0.48) BTKTTBK1TTBK2RETJAK2
SCHEMBL1229660 0.89 BTK (0.55) BTKTTBK1TTBK2RETJAK2
SCHEMBL12901011 0.87 SNCA (0.41) BTKJAK2JAK1TYK2SNCA
SCHEMBL19371944 0.86 BTK (0.51) BTKTTBK1TTBK2RETJAK2
SCHEMBL1230583 0.84 TTBK1 (0.46) BTKTTBK1TTBK2RETEGFR
SCHEMBL1229602 0.81 RET (0.58) BTKTTBK1TTBK2RETEGFR
SCHEMBL27968936 0.81 EGFR (0.45) BTKTTBK1TTBK2RETEGFR
SCHEMBL1229719 0.81 RET (0.52) BTKTTBK1TTBK2RETEGFR
SCHEMBL1231348 0.80 NPC1 (0.46) BTKTTBK1TTBK2RETEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011017009-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO claimed
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP disclosed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US disclosed
WO-2011017009-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed
WO-2011017009-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277228-A1 Novel Azaheterocyclic Compounds PCNA, MCL1, MYC BTK 1704/4885TTBK1 1515/4885TTBK2 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.